CorMedix (CRMD) Research & Development (2010 - 2025)

CorMedix (CRMD) has 15 years of Research & Development data on file, last reported at -$2.7 million in Q4 2025.

• For the quarter ending Q4 2025, Research & Development fell 110.22% year-over-year to -$2.7 million; the trailing twelve-month figure through Dec 2025 stood at $14.1 million (down 60.22% YoY), and the FY2025 full-year result was $19.3 million, down 32.72% from the prior year.
• Research & Development declined to -$2.7 million in Q4 2025, from $11.2 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $26.5 million in Q4 2024 to a low of -$2.7 million in Q4 2025.
• A 5-year average of $4.4 million and a median of $3.2 million in 2023 frame the typical range for Research & Development.
• Peak annual rise in Research & Development reached 1438.41% in 2025, while the deepest fall reached 110.22% in 2025.
• Tracing CRMD's Research & Development over 5 years: stood at $3.2 million in 2021, then retreated by 12.12% to $2.8 million in 2022, then increased by 12.53% to $3.2 million in 2023, then surged by 728.93% to $26.5 million in 2024, then slumped by 110.22% to -$2.7 million in 2025.
• Business Quant data shows CRMD's Research & Development at -$2.7 million in Q4 2025, $11.2 million in Q3 2025, and $2.4 million in Q2 2025.